Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer-Reference-Cited by-同舟云学术

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer

Published:2024-03 Issue:3 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Wang Yu¹,Zhang Tao¹,Yang Yin¹,Wang Jianyang¹,Li Canjun¹,Xu Xin¹,Wu Yuqi¹,Jiang Ying¹,Duan Jinghao¹,Wang Luhua²,Bi Nan¹³^ORCID

Affiliation:

1. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China

3. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1619

Reference10 articles.

1. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

2. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients

3. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

4. The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients

5. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution